{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:19:24Z","timestamp":1771427964798,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04514-2","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T18:34:09Z","timestamp":1769625249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Qingkai","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"5","key":"4514_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Comp\u00e9rat E, Dimitropoulos K, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol. 2025;87(5):582\u2013600. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019.","journal-title":"Eur Urol"},{"issue":"1","key":"4514_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40779-025-00599-y","volume":"12","author":"DC Feng","year":"2025","unstructured":"Feng DC, Li DX, Wu RC, Wang J, Xiao YH, Yoo KH, et al. Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046. Military Med Res. 2025;12(1):12. https:\/\/doi.org\/10.1186\/s40779-025-00599-y.","journal-title":"Military Med Res"},{"key":"4514_CR3","doi-asserted-by":"publisher","first-page":"107230","DOI":"10.1016\/j.phrs.2024.107230","volume":"205","author":"Y Song","year":"2024","unstructured":"Song Y, Jiang S, Peng Y, Qin C, Du Y, Xu T. Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma. Pharmacol Res. 2024;205:107230. https:\/\/doi.org\/10.1016\/j.phrs.2024.107230.","journal-title":"Pharmacol Res"},{"issue":"5","key":"4514_CR4","doi-asserted-by":"publisher","first-page":"20220141","DOI":"10.1002\/EXP.20220141","volume":"3","author":"G Li","year":"2023","unstructured":"Li G, Song Z, Ru Y, Zhang J, Luo L, Yang W, et al. Small-molecule nanoprodrug with high drug loading and EGFR, PI3K\/AKT dual-inhibiting properties for bladder cancer treatment. Explor (Beijing). 2023;3(5):20220141. https:\/\/doi.org\/10.1002\/EXP.20220141.","journal-title":"Explor (Beijing)"},{"key":"4514_CR5","doi-asserted-by":"publisher","unstructured":"Lindskrog SV, Strandgaard T, Nordentoft I, Galsky MD, Powles T, Agerb\u00e6k M et al. Circulating tumour DNA and Circulating tumour cells in bladder cancer - from discovery to clinical implementation. Nat Rev Urol 2025https:\/\/doi.org\/10.1038\/s41585-025-01023-9","DOI":"10.1038\/s41585-025-01023-9"},{"key":"4514_CR6","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1038\/ncomms6426","volume":"5","author":"T Yasuhara","year":"2014","unstructured":"Yasuhara T, Suzuki T, Katsura M, Miyagawa K. Rad54B serves as a scaffold in the DNA damage response that limits checkpoint strength. Nat Commun. 2014;5:5426. https:\/\/doi.org\/10.1038\/ncomms6426.","journal-title":"Nat Commun"},{"key":"4514_CR7","doi-asserted-by":"publisher","unstructured":"Bokor BA, Abdolreza A, Kapt\u00e1s F, P\u00e1l M, Battyani Z, Sz\u00e9ll M, et al. Novel FANCI and RAD54B variants and the observed clinical outcomes in a Hungarian melanoma cohort. Int J Mol Sci. 2024;26(1). https:\/\/doi.org\/10.3390\/ijms26010023.","DOI":"10.3390\/ijms26010023"},{"issue":"9","key":"4514_CR8","doi-asserted-by":"publisher","first-page":"102354","DOI":"10.1016\/j.jbc.2022.102354","volume":"298","author":"P Liu","year":"2022","unstructured":"Liu P, Lin C, Liu L, Lu Z, Tu Z, Liu H. RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors. J Biol Chem. 2022;298(9):102354. https:\/\/doi.org\/10.1016\/j.jbc.2022.102354.","journal-title":"J Biol Chem"},{"key":"4514_CR9","doi-asserted-by":"publisher","first-page":"109341","DOI":"10.1016\/j.biopha.2019.109341","volume":"118","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Li X, Han Y, Ji T, Huang X, Gao Q, et al. RAD54B potentiates tumor growth and predicts poor prognosis of patients with luminal A breast cancer. Biomed Pharmacother. 2019;118:109341. https:\/\/doi.org\/10.1016\/j.biopha.2019.109341.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"4514_CR10","doi-asserted-by":"publisher","first-page":"e70595","DOI":"10.1096\/fj.202500423R","volume":"39","author":"Z Liu","year":"2025","unstructured":"Liu Z, Jia B, Zhai Z, Wu F, Jia B, Yang Z, et al. AP1M2 drives Gemcitabine-Cisplatin chemoresistance by enhancing RAD54B-Associated DNA repair in bladder cancer. FASEB J. 2025;39(10):e70595. https:\/\/doi.org\/10.1096\/fj.202500423R.","journal-title":"FASEB J"},{"issue":"1","key":"4514_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12672-024-01008-x","volume":"15","author":"Z Tuo","year":"2024","unstructured":"Tuo Z, Lin Y, Zhang Y, Gao L, Yu D, Wang J, et al. Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer. Discov Oncol. 2024;15(1):160. https:\/\/doi.org\/10.1007\/s12672-024-01008-x.","journal-title":"Discov Oncol"},{"issue":"2","key":"4514_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21147\/j.issn.1000-9604.2024.02.05","volume":"36","author":"S Chen","year":"2024","unstructured":"Chen S, Sun J, Zhou H, Lei H, Zang D, Chen J. New roles of tumor-derived exosomes in tumor microenvironment. Chin J Cancer Res. 2024;36(2):151\u201366. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.02.05.","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"4514_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.14336\/AD.2024.0327","volume":"16","author":"D Li","year":"2024","unstructured":"Li D, Yu Q, Wu R, Tuo Z, Zhu W, Wang J, et al. Chronobiology of the tumor microenvironment: implications for therapeutic strategies and Circadian-Based interventions. Aging DIS. 2024;16(2):645\u201357. https:\/\/doi.org\/10.14336\/AD.2024.0327.","journal-title":"Aging DIS"},{"key":"4514_CR14","doi-asserted-by":"publisher","unstructured":"Peipei O, Weiting Y, Jianqiao S, Ping C, Qingyun H, Jiaxin Y et al. Endocrine toxicity of immune checkpoint inhibitors: a network meta-analysis of the current evidence. 2024; 3(1):1\u201319. https:\/\/doi.org\/10.15212\/AMM-2023-0037","DOI":"10.15212\/AMM-2023-0037"},{"key":"4514_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.34133\/research.0360","volume":"7","author":"J Liu","year":"2024","unstructured":"Liu J, Liu W, Wan Y, Mao W. Crosstalk between exercise and immunotherapy: current Understanding and future directions. Research-China. 2024;7:360. https:\/\/doi.org\/10.34133\/research.0360.","journal-title":"Research-China"},{"issue":"1","key":"4514_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44. https:\/\/doi.org\/10.1186\/s12964-022-00854-y.","journal-title":"Cell Commun Signal"},{"issue":"7492","key":"4514_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322. https:\/\/doi.org\/10.1038\/nature12965.","journal-title":"Nature"},{"issue":"2","key":"4514_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152\u201365. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.009.","journal-title":"Cancer Cell"},{"issue":"7","key":"4514_CR19","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1158\/1078-0432.CCR-13-0759","volume":"20","author":"M Riester","year":"2014","unstructured":"Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, et al. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014;20(7):1873\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0759.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4514_CR20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/ijc.28121","volume":"133","author":"YJ Kim","year":"2013","unstructured":"Kim YJ, Yoon HY, Kim JS, Kang HW, Min BD, Kim SK, et al. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling. Int J Cancer. 2013;133(5):1135\u201342. https:\/\/doi.org\/10.1002\/ijc.28121.","journal-title":"Int J Cancer"},{"issue":"5","key":"4514_CR21","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-11-2271","volume":"18","author":"M Riester","year":"2012","unstructured":"Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012;18(5):1323\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2271.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"4514_CR22","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","volume":"28","author":"JS Lee","year":"2010","unstructured":"Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28(16):2660\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.25.0977.","journal-title":"J Clin Oncol"},{"issue":"7693","key":"4514_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 Blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"issue":"7391","key":"4514_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603\u20137. https:\/\/doi.org\/10.1038\/nature11003.","journal-title":"Nature"},{"issue":"D1","key":"4514_CR25","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49(D1):D1420\u201330. https:\/\/doi.org\/10.1093\/nar\/gkaa1020.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"4514_CR26","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, et al. Intratumoral CD4(+) T cells mediate Anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181(7):1612\u201325. https:\/\/doi.org\/10.1016\/j.cell.2020.05.017.","journal-title":"Cell"},{"issue":"3","key":"4514_CR27","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2(3):100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"Innov (Camb)"},{"issue":"6","key":"4514_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell SYST. 2015;1(6):417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell SYST"},{"issue":"5","key":"4514_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"issue":"1","key":"4514_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic analyses reveal Genotype-Immunophenotype relationships and predictors of response to checkpoint Blockade. Cell Rep. 2017;18(1):248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019.","journal-title":"Cell Rep"},{"key":"4514_CR31","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.2147\/OTT.S267734","volume":"13","author":"X Wang","year":"2020","unstructured":"Wang X, Bai Y, Zhang F, Yang Y, Feng D, Li A, et al. Targeted Inhibition of P4HB promotes cell sensitivity to gemcitabine in urothelial carcinoma of the bladder. Oncotargets Ther. 2020;13:9543\u201358. https:\/\/doi.org\/10.2147\/OTT.S267734.","journal-title":"Oncotargets Ther"},{"issue":"1","key":"4514_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40537-023-00844-y","volume":"10","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liu L, Weng S, Xu H, Xing Z, Ren Y, et al. BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors. J Big Data-Ger. 2023;10(1):165. https:\/\/doi.org\/10.1186\/s40537-023-00844-y.","journal-title":"J Big Data-Ger"},{"issue":"8","key":"4514_CR33","doi-asserted-by":"publisher","first-page":"101124","DOI":"10.1016\/j.tranon.2021.101124","volume":"14","author":"S Feng","year":"2021","unstructured":"Feng S, Liu J, Hailiang L, Wen J, Zhao Y, Li X, et al. Amplification of RAD54B promotes progression of hepatocellular carcinoma via activating the Wnt\/\u03b2-catenin signaling. Transl Oncol. 2021;14(8):101124. https:\/\/doi.org\/10.1016\/j.tranon.2021.101124.","journal-title":"Transl Oncol"},{"key":"4514_CR34","doi-asserted-by":"publisher","first-page":"107302","DOI":"10.1016\/j.phrs.2024.107302","volume":"206","author":"Z Tuo","year":"2024","unstructured":"Tuo Z, Zhang Y, Li D, Wang Y, Wu R, Wang J, et al. Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review. PHARMACOL RES. 2024;206:107302. https:\/\/doi.org\/10.1016\/j.phrs.2024.107302.","journal-title":"PHARMACOL RES"},{"key":"4514_CR35","doi-asserted-by":"publisher","unstructured":"Barone B, Finati M, Cinelli F, Fanelli A, Del GF, De Berardinis E, et al. Bladder cancer and risk factors: data from a Multi-Institutional Long-Term analysis on cardiovascular disease and cancer incidence. J Pers Med. 2023;13(3). https:\/\/doi.org\/10.3390\/jpm13030512.","DOI":"10.3390\/jpm13030512"},{"issue":"6","key":"4514_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.21147\/j.issn.1000-9604.2024.06.03","volume":"36","author":"D Li","year":"2024","unstructured":"Li D, Wu R, Yu Q, Tuo Z, Wang J, Yoo KH, et al. Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives. Chin J Cancer Res. 2024;36(6):596\u2013615. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.06.03.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"4514_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2478\/raon-2024-0007","volume":"58","author":"J Li","year":"2024","unstructured":"Li J, Geng H, Li X, Zou S, Xu X. RAD54B promotes gastric cancer cell migration and angiogenesis via the Wnt\/\u03b2-catenin pathway. Radiol Oncol. 2024;58(1):67\u201377. https:\/\/doi.org\/10.2478\/raon-2024-0007.","journal-title":"Radiol Oncol"},{"key":"4514_CR38","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2025.0861","author":"A Guijarro","year":"2025","unstructured":"Guijarro A, Allavena G, Pisciotta L, Nencioni A, Caffa I. Aging-Related mechanisms underlying carcinogenesis: therapeutic opportunities. Aging Dis. 2025. https:\/\/doi.org\/10.14336\/AD.2025.0861.","journal-title":"Aging Dis"},{"issue":"10","key":"4514_CR39","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11(10):2983\u201394. https:\/\/doi.org\/10.1016\/j.apsb.2021.01.003.","journal-title":"Acta Pharm Sin B"},{"key":"4514_CR40","doi-asserted-by":"publisher","first-page":"103594","DOI":"10.1016\/j.dnarep.2023.103594","volume":"133","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Mouw KW. DNA repair deficiency and the immune microenvironment: A pathways perspective. DNA Repair. 2024;133:103594. https:\/\/doi.org\/10.1016\/j.dnarep.2023.103594.","journal-title":"DNA Repair"},{"issue":"6","key":"4514_CR41","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845\u201365. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.014.","journal-title":"Cancer Cell"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04514-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04514-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04514-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:38:54Z","timestamp":1771425534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04514-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4514"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04514-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All tissue samples and clinical data were obtained with patients\u2019 informed consent in accordance with the Helsinki Declaration and approved by the institutional ethics committee of Shanghai Zhuoli Biotechnology Co., Ltd. (No. LLS M-15-01). As all data analyzed were derived from public databases and no human subjects were directly recruited by our institution, additional ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all patients prior to clinical data collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}